We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Sildenafil on Endothelial Function

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Rambam Health Care Campus.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00297544
First Posted: February 28, 2006
Last Update Posted: February 28, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by:
Rambam Health Care Campus
  Purpose
We are investigating the chronic effect of daily assumption of Viagra on the blood vessels function in patients with impotence. The study will include 2 groups: 1- patients with multiple risk factors, e.g. hypertension 2- patients with no cardiovascular risk factors

Condition Intervention
Impotence Drug: Viagra

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Educational/Counseling/Training
Official Title: Effect of Sildenafil on Endothelial Function

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • Improvement of endothelial function following Viagra treatment, according to platismographia.

Estimated Enrollment: 60
Study Start Date: October 2005
Detailed Description:
We are investigating the chronic effect of daily assumption of Viagra on the blood vessels function in patients with impotence. The study will include 2 groups: 1- patients with multiple risk factors, e.g. hypertension 2- patients with no cardiovascular risk factors
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 40-70
  • impotence
  • with and without hypertension, Hypercholesteremia or DM

Exclusion Criteria:

  • CHF: NYHA > II
  • Stable angina: CCS > II
  • Nitrate treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00297544


Contacts
Contact: Giris Jacob, Prof., MD, DSc 972-4-854-2467 g_jacob@rambam.health.gov.il
Contact: Yuram Vardi, Prof. , MD 972-4-854-2819 y_vardi@rambam.health.gov.il

Locations
Israel
Rambam Medical Center, Recanati Autonomic Dysfunction CTR Recruiting
Haifa, Israel, 31096
Contact: Giris Jacob, MD, DSc    972-4-854-2594    g_Jacob@rambam.health.gov.il   
Principal Investigator: Yuram Vardi, MD         
Sponsors and Collaborators
Rambam Health Care Campus
Pfizer
Investigators
Principal Investigator: Giris Jacob, Prof, MD, DSc Rambam Health Care Campus
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00297544     History of Changes
Other Study ID Numbers: 1777-CTIL
First Submitted: February 27, 2006
First Posted: February 28, 2006
Last Update Posted: February 28, 2006
Last Verified: November 2005

Keywords provided by Rambam Health Care Campus:
impotence
endothelial function
autonomic nervous system

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents